Real-world response assessment of immune checkpoint inhibition: comparing iRECIST and RECIST 1.1 in melanoma and non-small cell lung cancer patients.

Christian NellesMoritz GräfPascale BernardThorsten PersigehlNils Große HokampDavid ZopfsDavid MaintzNicole KreuzbergJürgen WolfPaul J BröckelmannSimon Lennartz

Published in: European radiology (2024)

RECIST 1.1 may incorrectly assess atypical treatment patterns to immune checkpoint inhibitors. iRECIST better captured atypical response patterns compared to RECIST 1.1. iRECIST was more suitable for assessing response to immune checkpoint inhibitors in non-small cell lung carcinoma and melanoma.

Keyphrases

single cell
cell therapy
stem cells
mesenchymal stem cells
skin cancer